ILU Stock Overview
Offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for ILU from our risk checks.
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$134.28 |
| 52 Week High | US$150.56 |
| 52 Week Low | US$85.98 |
| Beta | 1.13 |
| 11 Month Change | 2.83% |
| 3 Month Change | 13.78% |
| 1 Year Change | 50.42% |
| 33 Year Change | -59.16% |
| 5 Year Change | -53.91% |
| Change since IPO | 758.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILU | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.5% | 0.9% | -0.02% |
| 1Y | 50.4% | 2.7% | 8.2% |
Return vs Industry: ILU exceeded the German Life Sciences industry which returned 2.7% over the past year.
Return vs Market: ILU exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| ILU volatility | |
|---|---|
| ILU Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: ILU has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ILU's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,615 | Jacob Thaysen | www.illumina.com |
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Illumina, Inc. Fundamentals Summary
| ILU fundamental statistics | |
|---|---|
| Market cap | €21.34b |
| Earnings (TTM) | -€1.52b |
| Revenue (TTM) | €4.22b |
5.1x
P/S Ratio-14.0x
P/E RatioIs ILU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILU income statement (TTM) | |
|---|---|
| Revenue | US$4.39b |
| Cost of Revenue | US$1.42b |
| Gross Profit | US$2.97b |
| Other Expenses | US$4.55b |
| Earnings | -US$1.58b |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.99 |
| Gross Margin | 67.61% |
| Net Profit Margin | -36.10% |
| Debt/Equity Ratio | 93.6% |
How did ILU perform over the long term?
See historical performance and comparison